15.95
-0.17 (-1.05%)
| Previous Close | 16.12 |
| Open | 16.06 |
| Volume | 97,121 |
| Avg. Volume (3M) | 220,720 |
| Market Cap | 2,040,674,816 |
| Price / Earnings (Forward) | 454.55 |
| Price / Sales | 107.16 |
| Price / Book | 4.47 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 |
| Operating Margin (TTM) | -633.21% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 27.34% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -42.54 M |
| Levered Free Cash Flow (TTM) | -13.46 M |
| Return on Assets (TTM) | -4.85% |
| Return on Equity (TTM) | -21.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Mesoblast Limited | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.33 |
|
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 3.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Prosperity Wealth Management, Inc. | 30 Jun 2025 | 50,100 |
| Rockbridge Investment Management, Lcc | 30 Jun 2025 | 49,150 |
| Lazari Capital Management, Inc. | 30 Jun 2025 | 46,471 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® |
| 27 Aug 2025 | Announcement | Mesoblast Financial Results and Corporate Update Webcast |
| 17 Jul 2025 | Announcement | Successful Commercial Launch of Ryoncil® |
| 08 Jul 2025 | Announcement | Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth |
| 30 Jun 2025 | Announcement | Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation |
| 30 Jun 2025 | Announcement | Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure |
| 11 Jun 2025 | Announcement | Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |